ArticleCancer science2020
Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.
Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 81 citations in OpenAlex.
- Injectable Thermosensitive Hydrogel Targeting STAT3 Reprograms Neutrophils to Amplify Anti-Tumor Immunity Post-Radiofrequency Ablation in HCC.Advanced healthcare materials · 2026Article
- KAN-PROSPECT: a Kolmogorov-Arnold Networks-integrated framework for predicting the effects and adverse reactions of natural products via transfer learning.Scientific reports · 2026Article
- Efficacy and safety analysis of TACE combined with lenvatinib and icaritin in unresectable hepatocellular carcinoma with poor performance status.BMC cancer · 2026Article
- Icaritin eliminates tumor-associated macrophages via STX16-dependent extracellular vesicle delivery of autophagosomes from hepatocellular carcinoma cells.Journal of experimental & clinical cancer research : CR · 2026Article
- The inflammatory state of tumor peripheral liver tissue affects hepatocellular carcinoma progression and prognosis.Discover oncology · 2026Article
- Interleukin-6/interleukin-10 ratio and immune dysregulation after radiofrequency ablation.World journal of hepatology · 2026Article
- The therapeutic potential of epimedium and its bioactive flavonoids in hepatitis and cirrhosis: an integrative review.Frontiers in cellular and infection microbiology · 2026Review
- The multifaceted regulatory effect of icariin on macrophages: a mini-review.Frontiers in immunology · 2026Review
- Schisandrin A suppresses hepatocellular carcinoma and sensitizes to sorafenib via modulating retinol metabolism.American journal of cancer research · 2026Article
- Dual role of icaritin in attenuating allograft rejection and exerting antitumor effects in mice.Frontiers in immunology · 2026Article
- Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study.Frontiers in immunology · 2026Article
- Icariin mediates autophagy and apoptosis of hepatocellular carcinoma cells induced by the β-catenin signaling pathway through lncRNA LOXL1-AS1.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Natural anti-cancer products: insights from herbal medicine.Chinese medicine · 2025Review
- First-Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR: A Case Report.Cancer reports (Hoboken, N.J.) · 2025Article
- The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.MedComm · 2025Review
- Phytomolecules from Herbs: Possible Effective Way for the Treatment of Liver Cancer.Current topics in medicinal chemistry · 2025Review
- Small-molecule-based targeted therapy in liver cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.Molecular cancer · 2024Review
- Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications.Biomarker research · 2024Review
- Chinese expert consensus on refined diagnosis, treatment, and management of advanced primary liver cancer (2023 edition).Liver research (Beijing, China) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 1 country.
Funding
Abstract
Advanced hepatitis B virus (HBV)-related hepatocellular carcinoma HCC with poor prognosis is often associated with chronic inflammation, immune tolerance, and marked heterogeneity. The interleukin-6 (IL-6)/JAK/STAT3 signal pathways play multiple regulatory roles in modulating inflammation and immunity in cancers. Polarization of myeloid-derived suppressor cells (MDSCs) is involved in HBV-related immunosuppression and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.